Patrizia Hrelia
Overview
Explore the profile of Patrizia Hrelia including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
166
Citations
2271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bortolotti S, Angelucci S, Montemurro L, Bartolucci D, Raieli S, Lampis S, et al.
Cancers (Basel)
. 2023 Feb;
15(3).
PMID: 36765949
Small-cell lung cancer (SCLC) is the most aggressive lung cancer type, and is associated with smoking, low survival rate due to high vascularization, metastasis and drug resistance. Alterations in family...
12.
Lenzi M, Turrini E, Catanzaro E, Cocchi V, Guerrini A, Hrelia P, et al.
Pharmaceuticals (Basel)
. 2022 Dec;
15(12).
PMID: 36558942
Little is known about the pharmacological activity of Ammodaucus leucotrichus Coss. & Dur., a small annual species that grows in the Saharan and sub-Saharan countries. In the present study, we...
13.
Graziosi A, Sita G, Corrieri C, Angelini S, dEmmanuele di Villa Bianca R, Mitidieri E, et al.
Int J Mol Sci
. 2022 Dec;
23(23).
PMID: 36498866
Endocrine-disrupting chemicals (EDCs) are different natural and synthetic chemicals that may interfere with several mechanisms of the endocrine system producing adverse developmental, metabolic, reproductive, and neurological effects in both human...
14.
Gasperini S, Bilel S, Cocchi V, Marti M, Lenzi M, Hrelia P
Int J Mol Sci
. 2022 Nov;
23(22).
PMID: 36430883
Three fentanyl analogues Acrylfentanyl, Ocfentanyl and Furanylfentanyl are potent, rapid-acting synthetic analgesics that recently appeared on the illicit market of new psychoactive substances (NPS) under the class of new synthetic...
15.
Ravegnini G, Nannini M, Indio V, Serrano C, Gorini F, Astolfi A, et al.
Int J Mol Sci
. 2022 Oct;
23(20).
PMID: 36293105
Gastrointestinal stromal tumors (GISTs) harboring mutations in the gene occur in only about 5-7% of patients. The most common mutation is exon 18 D842V, which is correlated with specific clinico-pathological...
16.
Cocchi V, Javega B, Gasperini S, OConnor J, Lenzi M, Hrelia P
Biomolecules
. 2022 Oct;
12(10).
PMID: 36291694
Autophagy is a fundamental catabolic process of cellular survival. The role of autophagy in cancer is highly complex: in the early stages of neoplastic transformation, it can act as a...
17.
Bartolucci D, Montemurro L, Raieli S, Lampis S, Pession A, Hrelia P, et al.
Cancers (Basel)
. 2022 Sep;
14(18).
PMID: 36139583
Among childhood cancers, neuroblastoma is the most diffuse solid tumor and the deadliest in children. While to date, the pathology has become progressively manageable with a significant increase in 5-year...
18.
Bartolucci D, Pession A, Hrelia P, Tonelli R
Pharmaceutics
. 2022 Jul;
14(7).
PMID: 35890348
Cancer incidence and mortality continue to increase, while the conventional chemotherapeutic drugs confer limited efficacy and relevant toxic side effects. Novel strategies are urgently needed for more effective and safe...
19.
Ravegnini G, Gorini F, Dondi G, Tesei M, De Crescenzo E, Morganti A, et al.
Front Oncol
. 2022 Jun;
12:847974.
PMID: 35747791
Systematic Review Registration: PROSPERO (CRD42021277980).
20.
Ravegnini G, Fosso B, Ricci R, Gorini F, Turroni S, Serrano C, et al.
Cancer Sci
. 2022 May;
113(8):2590-2599.
PMID: 35633186
Preclinical forms of gastrointestinal stromal tumor (GIST), small asymptomatic lesions, called microGIST, are detected in approximately 30% of the general population. Gastrointestinal stromal tumor driver mutation can be already detected...